Verrica Pharmaceuticals is focused on developing innovative dermatological therapeutics, particularly for viral skin diseases. Their lead product candidate, VP-102, is a proprietary drug-device combination that utilizes a GMP-controlled formulation of cantharidin, delivered through a single-use applicator. This design allows for precise topical dosing and targeted administration, making it suitable for treating conditions such as molluscum contagiosum, common warts, and external genital warts. The company emphasizes the importance of addressing the significant unmet needs in dermatology, particularly for common warts, which currently lack FDA-approved treatments.

In addition to VP-102, Verrica is advancing other product candidates, including VP-103 and VP-315, through various stages of clinical development. Their commitment to innovation is reflected in their clinical programs, which are designed with a deep understanding of the patient journey and the healthcare-provider landscape. By focusing on the development and commercialization of novel treatments, Verrica aims to provide significant benefits to underserved patients who have limited options for satisfactory medical care.

United States

At Verrica Pharmaceuticals, we are dedicated to easing the strain of hard-to-treat viral skin infections affecting millions of underserved patients. We are initially developing a topical therapy for the treatment of molluscum contagiosum, a highly contagious and primarily pediatric viral skin disease, and common warts. There is currently no FDA-approved treatment nor is there an established standard of care for either of these diseases, resulting in significant undertreated populations in two of the largest unmet needs in dermatology.


Cancer

Infectious Diseases

Skin Diseases

Verrica Pharmaceuticals

Infectious disease

Molluscum contagiosum

Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.

YCANTH (VP-102)

Genital Warts

Human papillomavirus

Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration.

Verrica Pharmaceuticals

Company Details